- Genetic Technologies Limited GENE will launch a ‘World First’ Comprehensive Risk Assessment Test, which evaluates a woman’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.
- Combined with other clinical risk factors, the test provides a comprehensive risk assessment in a simple saliva test.
- Related: Genetic Technologies Shares Jump After Strategic Alliance With Qiagen.
- The new test integrates the patented and proprietary GeneType breast and ovarian cancer platform.
- GTG’s approach “appends” the detection of the 13 major “actionable” breast and ovarian cancer susceptibility genes to the GeneType test platform.
- Results in a higher classification rate of women at elevated risk of breast and ovarian cancer than traditional clinical tools by assessing breast and ovarian cancer susceptibility from both rare and common genetic variants and other known clinical risk factors associated with the development of both diseases.
- Advances the goal of providing population-based genetic screening for Breast and Ovarian cancer where up to 85% of cancers diagnosed do not have hereditary or family history.
- The test will be launched via Business to Business (‘B2B’) and Consumer Initiated Testing (‘CIT’) channels in the U.S. and will be showcased at the BRCA 2023 Symposium in early May.
- Price Action: GENE shares are up 193.10% at $2.96 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
